- |||||||||| ozagrel ophthalmic (KCT-0809) / Teika, Ono Pharma, Kissei
Trial completion, Trial primary completion date: A Long-term Study of KCT-0809 in Dry Eye Patients With Sjögren's Syndrome (clinicaltrials.gov) - Nov 18, 2017 P3, N=0, Completed, Recruiting --> Terminated | Trial primary completion date: Apr 2018 --> May 2017; Discontinuation of the development Recruiting --> Completed | Trial primary completion date: Apr 2018 --> Oct 2017
- |||||||||| ozagrel ophthalmic (KCT-0809) / Teika, Ono Pharma, Kissei
Trial completion, Trial primary completion date: A Phase III Study of KCT-0809 in Dry Eye Patients With Sjögren's Syndrome (clinicaltrials.gov) - May 17, 2017 P3, N=0, Completed, Recruiting --> Completed | Trial primary completion date: Apr 2018 --> Oct 2017 Recruiting --> Completed | Trial primary completion date: Jun 2017 --> Jan 2017
- |||||||||| ozagrel ophthalmic (KCT-0809) / Teika, Ono Pharma, Kissei
Trial completion, Trial primary completion date: A Late Phase II Study of KCT-0809 in Patients With Dry Eye Syndromes (clinicaltrials.gov) - Oct 20, 2015 P2, N=0, Completed, Recruiting --> Completed | Trial primary completion date: Jun 2017 --> Jan 2017 Active, not recruiting --> Completed | Trial primary completion date: Jun 2014 --> Mar 2014
- |||||||||| ozagrel ophthalmic (KCT-0809) / Teika, Ono Pharma, Kissei
Enrollment closed: A Late Phase II Study of KCT-0809 in Patients With Dry Eye Syndromes (clinicaltrials.gov) - May 28, 2014 P2, N=0, Active, not recruiting, Active, not recruiting --> Completed | Trial primary completion date: Jun 2014 --> Mar 2014 Recruiting --> Active, not recruiting
- |||||||||| ozagrel ophthalmic (KCT-0809) / Teika, Ono Pharma, Kissei
Enrollment closed, P2 data: A Parallel Group Phase II Study of KCT-0809 in Patients With Dry Eye Syndromes (clinicaltrials.gov) - Apr 30, 2013 P2, N=0, Active, not recruiting, Active, not recruiting --> Completed Recruiting --> Active, not recruiting
|